All News
Filter News
Found 1,147 articles
-
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
7/6/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’s Scientific Advisory Board.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022
7/5/2022
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022.
-
Provention Bio announced the FDA extended its review period by three months for the Biologics License Application (BLA) of its diabetes prevention drug, teplizumab to Nov. 17.
-
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
6/27/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), today announced that data on its lead compound CPI-613® (devimistat) in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer will be presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022.
-
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
6/24/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) for its investigational gene therapy, valoctocogene roxaparvovec.
-
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
6/21/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO® (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed.
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
6/16/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
6/16/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism.
-
Acadia Surges After FDA Published Briefing Documents for Alzheimer's-Related Psychosis Therapeutic
6/15/2022
Shares of Acadia are up more than 12% in early trading after the FDA published briefing documents related to its supplemental NDA for antipsychotic therapeutic. -
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
6/13/2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of achondroplasia, the most common form of disproportionate short stature.
-
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
6/8/2022
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma.
-
Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.
-
Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights
6/6/2022
The company announces new mass spectrometry instruments, workflows, software and industry collaborations during ASMS 2022 Conference.
-
NYC Metro Now Tops All Other Regions in U.S. for Life Sciences Jobs and Funding
6/3/2022
Beating out San Francisco and Boston, new report shows New York City Metro Area has the Most Life Sciences Employment Opportunities in the Country.
-
Thermo Fisher Scientific Releases Corporate Social Responsibility Report
6/2/2022
Report highlights progress toward environmental, social and governance objectives.
-
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
6/1/2022
Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology Annual Meeting taking place June 3 – June 7, 2022 in Chicago.
-
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
5/31/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.
-
Green Scientific Labs Achieves ISO/IEC 17025 Recertification for Florida & Arizona Testing Laboratories
5/31/2022
Green Scientific Labs Holdings Inc. ("Green Scientific Labs" or the "Company"), leading multi-state provider of innovative cannabis and hemp testing technologies and methods, has achieved International Organization for Standardization (ISO) ISO/IEC 17025 recertification in both its Florida and Arizona laboratories.
-
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
5/19/2022
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc.
-
Thermo Fisher Scientific Declares Quarterly Dividend - May 19, 2022
5/19/2022
Thermo Fisher Scientific Inc., the world leader in serving science, announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.